Field cancerization and oral leukoplakia

Field Cancerization: Basic Science and Clinical Applications

Volumn , Issue , 2011, Pages 93-112

  Feller, Liviu ^a   Lemmer, Johan ^a,b  

^a SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895273520     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (64)

1. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J. Oral. Pathol. Med. 2007; 36: 575-580.
2. Neville RW, Damm DD, Allen CM, Buquot JE. Oral and maxillofacial pathology. 3rd Edition. China, Saunders Elsevier; 2009, Chapter 10: pg 388-397.
3. Warnakulasuriya S. Histological grading of oral epithelial dysplasia: revisted. J. Pathol. 2001; 194:294-297.
4. Thomson PJ. Field change and oral cancer: new evidence for widespread carcinogenesis? Int. J. Oral. Maxillofac. Surg. 2002; 31:262-266.
5. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996; 56:2488-2492.
6. Tabor MP, Brakenhoff RH, van Houten VMM, Alain Kummer J, Snel MHJ, Snijders PJF, Snow GB, Leemans CR, Braakhuis BJM. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin. Cancer Res. 2001; 7:1523-1532.
7. Tabor MP, Braakhuis BJM, van der Wal JE, van Diest PJ, Leemans CR, Brakenhoff RH, Kummer JA. Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J. Pathol. 2003; 199:354-360.
8. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJM. Genetically altered fields as origin of locally recurrent head and neck cancer: A retrospective study. Clin. Cancer Res. 2004; 10:3607-3613.
9. Braakhuis BJM, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003; 63:1727-1730.
10. Braakhuis BJM, Brakenhoff RH, Leemans CR. Second field tumours: A new opportunity for cancer prevention? Oncologist 2005; 10:493-500.
11. Ha PK, Califano JA. The molecular biology of mucosal field cancerization of the head and neck. Crit. Rev. Oral. Biol. Med. 2003; 14:363-369.
12. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane database of systematic reviews 2006, Issue 4. Art No.: CD001829. DOI:10.1002/14651858.CD001829.pub3.
13. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical histopathological, and molecular biological characteristics. Crit. Rev. Oral. BIol. Med. 2003; 14:47-62.
14. Suarez P, Batsakis JG, El-Naggar AK. Leukoplakia: Still a gallimaufry or is progress being made? A review. Adv. Anat. Pathol. 1998; 5:137-155.
15. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J. Oral. Pathol. Med. 2008; 37:1-10.
16. Scully C, Sudbø J, Speight PM. Progress in determining the malignant potential of oral lesions. J. Oral. Pathol. Med. 2003; 32:251-256.
17. Holmstrup P, Vedtofte P, Reibel J, Stolze K. Long-term treatment outcome or oral premalignant lesions. Oral. Oncol. 2006; 42:461-474.
18. van der Waal I, Axéll T. Oral leukoplakia: a proposal for uniform reporting. Oral. Oncol. 2002; 38:521-526.
19. Reichart PA, Philipsen HP. Oral erythroplakia-a review. Oral. Oncol. 2005; 41:551-561.
20. Feller L, Wood NH, Raubenheimer EJ. Proliferative verrucous leukoplakia and field cancerization: Report of a case. J. Int. Acad. Periodontol. 2006; 8:67-70.
21. Bagan JV, Murillo J, Poveda R, Gavalda C, Jimenez Y, Scully C. Proliferative verrucous leukoplakia: unusual locations of oral squamous cell carcinomas, and field cancerization as shown by the appearance of multiple OSCCs. Oral. Oncol. 2004; 40:440-443.
22. Silverman S Jr, Gorsky M. Proliferative verrucous leukoplakia. A follow-up study of 54 cases. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 1997; 84:154-157.
23. Cabay RJ, Morton TH Jr, Epstein JB. Proliferative verrucous leukoplakia and its progression to oral carcinoma: a review of the literature. J. Oral. Pathol. Med. 2007; 36:255-261.
24. Zakrzewska JM, Lopes V, Speight P, Hopper C. Proliferative verrucous leukoplakia. A report of ten cases. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 1996; 82:396-401.
25. Partridge M, Pateromichelakis S, Phillips E, Emilion GG, A'Hern RP, Langdon JD. A case control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res. 2000; 60:3893-3898.
26. Zhang L, Cheung KJ Jr, Lam WL, Cheng X, Poh C, Priddy R, Epstein J, Le ND, Rosin MP. Increased genetic damage in oral leukoplakia from high risk sites. Potential impact on staging and clinical management. Cancer 2001; 91:2148-2155.
27. Dietrich T, Reichart PA, Scheifele C. Clinical risk factors of oral leukoplakia in a representative sample of the US population. Oral. Oncol. 2004; 40:158-163.
28. Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 1995; 79:321-329.
29. Lodi G, Porter S. Management of potentially malignant disorders: evidence and critique. J. Oral. Pathol. Med. 2008; 37:63-69.
30. Feller L, Altini M, Slabbert H. Pre-malignant lesions of the oral mucosa in a South African sample-a clinicopathological study. J. Dent. Assoc. S. Afr. 1991; 46:261-265.
31. Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral. Oncol. 2003; 39:770-780.
32. Warnakulasuriya S, Reibel J, Bouqout J, Dabelsteen. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J. Oral. Pathol. Med. 2008; 37:127-133.
33. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakic and malignant transformation. A follow up study of 257 patients. Cancer 1984; 53:563-568.
34. Holmstrup P, Vedtofte P, Reibel J, Stolze K. Oral premalignant lesions: is a biopsy reliable? J. Oral. Pathol. Med. 2007; 36:262-266.
35. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL. Clinical implications and utility of field cancerization. Cancer Cell Int. 2007; 7:2.
36. Rhiner C, Moreno E. Super competition as a possible mechanism to pioneer pre-cancerous fields. Carcinogenesis 2009; 30:723-728.
37. Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, Clayman G, Lee JJ, Lee JS, Hittelman WN, Lippman SM, Hong WK. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J. Natl. Cancer Instit. 1998; 90: 1545-1551.
38. Lichtenstein AV. On evolutionary origin of cancer. Cancer Cell Int. 2005; 5:5.
39. Nanci A. Ten Cate's Oral Histology. Development, structure and function. 7th Edition. Missouri: Mosby Elsevier; 2008, Chapter 12: pg 319-357.
40. Loeb LA. A mutator phenotype in cancer. Cancer Res. 2001; 61:3230-3239.
41. Mandard AM, Hainaut P, Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res. 2000; 462:335-342.
42. Jin C, Jin Y, Wennerberg J, Åkervall J, Dictor M, Mertens F. Karyotypic heterogeneity and clonal evolution in squamous cell carcinomas of the head and neck. Cancer genet. Cytogenet. 2002; 132:85-96.
43. Jang SJ, Chiba I, Hirai A, Hong WK, Mao L. Multiple oral squamous epithelial lesions: are they genetically related? Oncogene 2001; 20:2235-2242.
44. van Oijen MGCT, Slootweg PJ. Oral field cancerization: carcinogen-induced independent events or micrometastatic deposits? Cancer Epidemiol, Biomarkers Prev. 2000; 9:249-256.
45. Kim MM, Califano JA. Molecular pathology of head-and-neck cancer. Int. J. Cancer 2004; 112:545-553.
46. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Berean K, Epstein JB, Priddy R, Le ND, Zhang L. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin. Cancer Res. 2000; 6:357-362.
47. Garnis C, Buys TP, Lam WL. Genetic alteration and gene expression modulation during cancer progression. Mol. Cancer 2004; 3:9.
48. Grizzi F, Di Ieva A, Russo C, Frezza EE, Cobos E, Muzzio PC, Chiriva-Internati M. Cancer initiation and progression: an unsimplifiable complexity. Theor Biol. Med. Model. 2006; 3:37.
49. Warnakulasuriya S. Lack of molecular markers to predict malignant potential of oral precancer. J. Pathol. 2000; 190:407-409.
50. Greenspan D, Jordan RCK. The white lesion that kills-Aneuploid dysplastic oral leukoplakia. N. Eng. J. Med. 2004; 350:1382-1384
51. Ha PK, Tong BC, Westra WH, Sanchez-Cespedes M, Parrella P, Zahurak M, Sidransky D, Califano JA. Mitochondrail C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin. Cancer Res. 2002; 8:2260-2265.
52. Sudbø J, Kildal W, Risberg B, Koppang HS, Danielsen HE, Reith A. DNA content as a prognostic marker in patients with oral leukoplakia. N. Engl. J. Med. 2001; 344:1270-1278.
53. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM. TP53 mutations and survival in squamous cell carcinoma of the head and neck. N. Engl. J. Med. 2007; 357:2552-2561.
54. Jin YT, Myers J, Tsai ST, Goepfert H, Batsakis JG, El-Naggar AK. Genetic alterations in oral squamous cell carcinoma of young adults. Oral. Oncol. 1999; 35:251-256.
55. Santos-García A, Abad-Hernández MM, Fonseca-Sánchez E, Cruz Hernández JJ, Bullón-Sopelana A. Proteic expression of p53 and cellular proliferation in oral leukoplakias. Med. Oral. Patol. Oral. Cir. Bucal. 2005; 10:1-8.
56. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, Hittleman W, Hong WK. Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premaligant lesions and their value in cancer risk assessment. Nat. Med. 1996; 2:682-685.
57. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin. Cancer Res. 2000; 6:1702-1710.
58. Zhang L, Williams M, Poh CF, Laronde D, Epstein JB, Durham S, Nakamura H, Berean K, Hovan A, Le ND, Hislop G, Priddy R,. Hay J, Lam WL, Rosin MP. Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. Cancer Res. 2005; 65:8017-8021.
59. Sudbø J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbø A, Sagen S, Bryne M, El-Naggar A, Risberg B, Evensen JF, Reith A. The influence of resection and aneuploidy on mortality in oral leukoplakia. N. Engl. J. Med. 2004; 350:1405-1413.
60. Jin C, Jin Y, Wennerberg J, Åkervall J, Grenthe B, Mandahl N, Heim S, Mitelman F, Mertens F. Clonal chromosome aberrations accumulate with age in upper aerodigestive tract mucosa. Mutat Res. 1997; 374:63-72.
61. Zhang L, Rosin MP. Loss of heterozygosity: a potential tool in management of oral premalignant lesion? J. Oral. Pathol. Med. 2001; 30:513-520.
62. Weber F, Xu Y, Zhang L, Patocs A, Shen L, Platzer P, Eng C. Microenvironmental genomic alterations and clinicopathological behaviour in head and neck squamous cell carcinoma. JAMA 2007; 297:187-195.
63. Baker SG, Kramer BS. Paradoxes in carcinogenesis: New opportunities for research directions. BMC Cancer; 2007; 7:151.
64. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278:1073-1077.